Xenetic Biosciences Q1 net loss narrows 49.5% to $456,382

• Xenetic Biosciences posted a net loss of USD 456,382 for quarter ended March 31, 2026, narrowing 49.5%.
• Revenue rose 36% to USD 806,923, driven by higher royalty revenue.
• Operating loss narrowed 46.7% to USD 502,117 as operating costs and expenses fell 14.8% to USD 1.31 million.
• Research and development expense dropped 24.8% to USD 661,443, while general and administrative expense edged down 1.4% to USD 647,597.
• Board launched a formal strategic review that includes options such as a sale of the company or assets, a business combination, or a reverse merger, while continuing to advance its systemic DNase program toward the clinic.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenetic Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-26-003727), on May 12, 2026, and is solely responsible for the information contained therein.